Journavx (suzetrigine) PDUFA Date (Vertex Pharmaceuticals)
FDA PDUFA decision date for Journavx (suzetrigine) is January 30, 2025. Developed by Vertex Pharmaceuticals. Indication: Moderate-to-severe acute pain. Current status: Approved.
Indication
Moderate-to-severe acute pain
Regulatory details
- Company: Vertex Pharmaceuticals
- Therapeutic area: Pain / CNS
- Application type: NDA
- Review type: Priority
- PDUFA date: 2025-01-30
- Outcome: Approved